Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Recruiting now · Phase 1/Phase 2

Conditions studied: Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumours (NET), Adrenal Tumours, DIPG, Glioblastoma, Glioblastoma (GBM), Osteosarcoma Recurrent, Carcinoma Adrenal, Synovial Sarcomas, Esthesioneuroblastoma, Neuroblastoma Recurrent, Solid Tumor Refractory to Conventional Treatment, Medulloblastoma Recurrent, Paraganglioma/ Phaeochromocytoma, Ependymoma, Ependymoma Recurrent

In brief

Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)

Key facts

Study ID

NCT06607692

Run by

Fundación de investigación HM

People needed

25

Starts

2024-09-20

Expected to finish

2029-12-01

Last updated by the study team

2026-06-04

Who can join

Age: 3 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 months - 18 years of age at the time of the initial diagnosis.
• ≥ 3 years at the moment of inclusion in the trial.
• Diagnosis: relapsed/refractory solid tumours with positive uptake on SSTR-PET (PET-CT or PET-MRI), performed in the previous three months before entering the study.
• The evaluation of SSTR expression will be classified according to a qualitative 4-point scale: SSTR expression V (visual score):
• Score = 0: Below or equal to blood pool
• Score = 1: Above blood pool and lower than liver
• Score = 2: Equal to or above liver and lower than spleen
• Score = 3: Equal to or above spleen
• Patients with scores ≥ 2 in the majority of the tumoral lesions will be considered to have a positive SSTR-PET and will be therefore eligible for the trial. Patients with a higher score are presumed to have a better response to the treatment.
• It is admissible to have non-measurable disease only (e.g., HR-NB with bone-only or bone-marrow-only active disease).
• Performance status ≥ 50% according to Lansky scale (<16 years old) or Karnofsky scale (for ≥16 years old).
• Life expectancy of at least 3 months.
• Availability of ability to swallow tablets or capsules.
• Adequate organ function within 28 days prior to enrolment, as defined by:
• Hb ≥10 g/dl (packed red blood transfusion is acceptable up to 24 hours prior starting treatment);
• White blood cell (WBC) count ≥ 2500/μL (equivalent to 2.5 x 109/L)
• Absolute Neutrophil Count (ANC) ≥ 1000/μl;
• Platelets ≥ 100.000/μl, without transfusion in the prior ≥7 days;
• Serum plasma creatinine ≤ 1.5 x upper limit of normal (ULN) OR estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2 (assessed by 2009-Schwartz formula).
• Total bilirubin ≤ 1.5 x the institutional ULN. For patients with known Gilbert's Syndrome ≤ 3.0 ULN is permitted.
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 3.0 ULN.
• Albumin >3.0 g/dL (3.0 g/dL is equivalent to 30 g/L)
• A negative serum or urine pregnancy test in women with onset of menses or ≥12 years of age.
• Patients of reproductive potential must agree to use highly effective contraceptive methods for the entire study duration and up to 7 months, in case of females, and 4 months in case of males, after the last dose of Lutathera, or up to 6 months, in case of females, and 3 months in case of males, after the last dose of olaparib, whichever takes places later.
• Have the ability to comprehend and willingness to provide written informed consent (ICF) for the study before patient registration or any trial-related screening procedures. If the patient is <18 years old, the written informed consent must be signed by the parent(s) or legal guardian(s) according to national regulations. In the case of patients between 12 and 17 years, they must sign an assent form, and if the patient turns 18 during their participation in the study, they must sign an informed consent form.

You may not qualify if…

• Previous significant drug-induced hepatitis toxicity experienced in the past that has required treatment dose reductions, treatment discontinuation or that, at the investigator discretion, could infer a risk.
• Having received more than one previous treatment with other radiolabelled somatostatin analogues.
• Inability to swallow tablets or capsules.
• Subjects who are currently receiving any other anticancer and/or investigational agents (e.g. chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies]). There must be at least 28 days of washout from any prior treatment. In case of checkpoints inhibitors, there should be at least 4 months of washout. Palliative Radiation Therapy for symptom control (e.g. pain relief) could be acceptable, at the discretion of the investigator.
• Treatment with long-acting somatostatin analogues within 28 days prior the administration of 177Lu-DOTATATE.
• Known hypersensitivity to any of the excipients.
• Subjects who have an uncontrolled infection.
• Lactating women.

Where it is running

• HM Monteprincipe — Boadilla del Monte, Madrid, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.